Novo bets on swift FDA review for oral diabetes drug semaglutide

The world’s top diabetes drug maker Novo Nordisk is in a hurry. As part of its fourth-quarter results on Friday, the company $NVO said it was planning to use a priority voucher to hasten the FDA review process for its potential blockbuster oral GLP-1, semaglutide, a critical component of the Danish drugmaker’s long-term growth strategy.